Get started
Author

Nataša Cmiljanović

Observed names: Cmiljanovic, Natasa, Cmiljanović, Nataša, N. Cmiljanovic, Natasa Cmiljanovic
OpenAlex ID: A5087724144
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
2017 · Florent Beaufils, Natasa Cmiljanovic, et al. · Journal of Medicinal Chemistry · 142
Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
2017 · Thomas Bohnacker, Andrea E. Prota, et al. · Nature Communications · 117
PDF
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
2018 · Andreas Wicki, Nicholas Brown, et al. · European Journal of Cancer · 65
PDF
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
2024 · Filip Janku, Grace M. Choong, et al. · Cancers · 14
PDF
Exon–Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation
2021 · Nicolas Munz, Luciano Cascione, et al. · Non-Coding RNA · 5
PDF
Abstract 4514: PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability
2015 · Vladimir Cmiljanovic, Robert A. Ettlin, et al. · Cancer Research · 5
A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.
2016 · Alex A. Adjei, Grace K. Dy, et al. · Journal of Clinical Oncology · 4
Abstract 2664: PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor
2015 · Vladimir Cmiljanovic, Natasa Cmiljanovic, et al. · Cancer Research · 3
Abstract 378: Exploring intermittent dosing schedules for the Pan PI3K/mTor inhibitor PQR309
2016 · Karin Jorga, Debora Schmitz, et al. · Cancer Research · 2
Abstract CT310: First-in-man (FIM) pharmacodynamic (PD) and pharmacokinetic (PK) phase I trial of PQR309 in advanced solid tumors
2015 · Andreas Wicki, Cristiana Sessa, et al. · Cancer Research · 1
Abstract 671: BKM120-mediated G2 arrest: Structural and functional segregation of off-target action and PI3K inhibition
2015 · Thomas Bohnacker, Florent Beaufils, et al. · Cancer Research · 1
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
2024 · Janku, Filip; https://orcid.org/0000-0002-8123-4065, Choong, Grace M, et al. · Zurich Open Repository and Archive (University of Zurich)
Abstract 2287: Final results of the pharmacodynamic (PD) data of PQR309-001, a first-in-human trial of a combined PI3K/mTOR inhibitor in advanced solid tumors
2016 · Andreas Wicki, Vincent Prêtre, et al. · Cancer Research
Early preclinical development of PQR309, a novel balanced dual PI3K/mTOR inhibitor for treatment of various cancer types
2015 · R. Ettlin, W. Dieterle, et al. · Toxicology Letters
Development of novel, potent and selective small molecular weight PI3K/mTOR inhibitors for the treatment of cancer
2011 · Cmiljanović, Nataša · edoc (University of Basel)
Works count: 16
Citation count: 359
H-index: 5
I10-index: 4
Year
Topic
Type